Search hospitals > Michigan > Novi
Henry Ford Medical Center-Columbus
Claim this profileNovi, Michigan 48377
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
139 reported clinical trials
5 medical researchers
Summary
Henry Ford Medical Center-Columbus is a medical facility located in Novi, Michigan. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Henry Ford Medical Center-Columbus is involved with conducting 139 clinical trials across 324 conditions. There are 5 research doctors associated with this hospital, such as Ding Wang, Haythem Y. Ali, Eleanor M. Walker, and Stuart Gordon.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
PR positive
ER positive
Top PIs
Ding WangHenry Ford Hospital5 years of reported clinical research
Expert in Cancer
Studies Non-Small Cell Lung Cancer
48 reported clinical trials
105 drugs studied
Haythem Y. AliHenry Ford Hospital5 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
39 reported clinical trials
103 drugs studied
Eleanor M. WalkerHenry Ford Hospital2 years of reported clinical research
Studies Cancer
Studies Squamous Cell Carcinoma
18 reported clinical trials
58 drugs studied
Stuart GordonHenry Ford Health System2 years of reported clinical research
Studies Cholangitis
Studies Liver Cirrhosis
13 reported clinical trials
16 drugs studied
Clinical Trials running at Henry Ford Medical Center-Columbus
Breast Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Lung Cancer
Bladder Cancer
Cancer
Bladder Carcinoma
Renal Cell Carcinoma
Urothelial Carcinoma
Prostate Cancer
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Henry Ford Medical Center-Columbus?
Henry Ford Medical Center-Columbus is a medical facility located in Novi, Michigan. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Henry Ford Medical Center-Columbus is involved with conducting 139 clinical trials across 324 conditions. There are 5 research doctors associated with this hospital, such as Ding Wang, Haythem Y. Ali, Eleanor M. Walker, and Stuart Gordon.